Tenuigenin ameliorates cognitive dysfunction in Alzheimer's disease via hippocampal neurogenesis enhancement

Kaili Lin; Zhu Zhang; Zhang Zhang; Wenjun Ding; Peili Zhu; Ying Wang; Xiaoli Jiang; Bin Liu; Ken Kin Lam Yung; Shiqing Zhang

doi:10.1016/j.phytol.2022.08.005

Tenuigenin ameliorates cognitive dysfunction in Alzheimer's disease via hippocampal neurogenesis enhancement

Kaili Lin, Zhu Zhang, Zhang Zhang, Wenjun Ding, Peili Zhu, Ying Wang, Xiaoli Jiang, Bin Liu^*, Ken Kin Lam Yung^*, Shiqing Zhang^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › peer-review

1 Citation (Scopus)

Abstract

A promising strategy for treating Alzheimer's disease (AD) is hippocampal neurogenesis enhancement. Tenuigenin (TEN) is a bioactive compound extracted from Polygala tenuifolia that is widely used for treating amnesia in Chinese medicine. However, whether TEN is effective in treating AD through hippocampal neurogenesis is not fully clear. This study aimed to explore the pharmacologic effect and underlying mechanism of TEN on hippocampal neurogenesis and cognitive deficit amelioration in AD. In an in vivo study, TEN administration significantly ameliorated the cognitive decline in APP/PS1 transgenic AD mice via enhancement of hippocampal neurogenesis, which might be attributed to activation of the GSK-3β/β-catenin pathway. Furthermore, an in silico study suggested that TEN might be directly targeted to GSK-3β. Overall, TEN enhanced hippocampal neurogenesis and consequently ameliorated cognitive deficits via GSK-3β/β-catenin pathway activation, indicating that TEN might be a promising novel agent for AD treatment.

Original language	English
Pages (from-to)	109-113
Number of pages	5
Journal	Phytochemistry Letters
Volume	51
Early online date	19 Aug 2022
DOIs	https://doi.org/10.1016/j.phytol.2022.08.005
Publication status	Published - Oct 2022

Scopus Subject Areas

Biotechnology
Biochemistry
Agronomy and Crop Science
Plant Science

User-Defined Keywords

Alzheimer's disease
Cognitive deficit
GSK-3β
Hippocampal neurogenesis
Tenuigenin

Access to Document

10.1016/j.phytol.2022.08.005

Cite this

@article{06aa968d7e614c89abbbe907c54cf490,

title = "Tenuigenin ameliorates cognitive dysfunction in Alzheimer's disease via hippocampal neurogenesis enhancement",

abstract = "A promising strategy for treating Alzheimer's disease (AD) is hippocampal neurogenesis enhancement. Tenuigenin (TEN) is a bioactive compound extracted from Polygala tenuifolia that is widely used for treating amnesia in Chinese medicine. However, whether TEN is effective in treating AD through hippocampal neurogenesis is not fully clear. This study aimed to explore the pharmacologic effect and underlying mechanism of TEN on hippocampal neurogenesis and cognitive deficit amelioration in AD. In an in vivo study, TEN administration significantly ameliorated the cognitive decline in APP/PS1 transgenic AD mice via enhancement of hippocampal neurogenesis, which might be attributed to activation of the GSK-3β/β-catenin pathway. Furthermore, an in silico study suggested that TEN might be directly targeted to GSK-3β. Overall, TEN enhanced hippocampal neurogenesis and consequently ameliorated cognitive deficits via GSK-3β/β-catenin pathway activation, indicating that TEN might be a promising novel agent for AD treatment.",

keywords = "Alzheimer's disease, Cognitive deficit, GSK-3β, Hippocampal neurogenesis, Tenuigenin",

author = "Kaili Lin and Zhu Zhang and Zhang Zhang and Wenjun Ding and Peili Zhu and Ying Wang and Xiaoli Jiang and Bin Liu and Yung, {Ken Kin Lam} and Shiqing Zhang",

note = "Funding Information: This study was financially supported by the grants of Guangdong Basic and Applied Basic Research Foundation (No.: 2019A1515011497 ), Foundation for Young Talents in Higher Education of Guangdong (No.: 2020KQNCX058 ), and Guangzhou Science and Technology Project (No.: 202102020932 ). Publisher Copyright: {\textcopyright} 2022 Phytochemical Society of Europe",

year = "2022",

month = oct,

doi = "10.1016/j.phytol.2022.08.005",

language = "English",

volume = "51",

pages = "109--113",

journal = "Phytochemistry Letters",

issn = "1874-3900",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Tenuigenin ameliorates cognitive dysfunction in Alzheimer's disease via hippocampal neurogenesis enhancement

AU - Lin, Kaili

AU - Zhang, Zhu

AU - Zhang, Zhang

AU - Ding, Wenjun

AU - Zhu, Peili

AU - Wang, Ying

AU - Jiang, Xiaoli

AU - Liu, Bin

AU - Yung, Ken Kin Lam

AU - Zhang, Shiqing

N1 - Funding Information: This study was financially supported by the grants of Guangdong Basic and Applied Basic Research Foundation (No.: 2019A1515011497 ), Foundation for Young Talents in Higher Education of Guangdong (No.: 2020KQNCX058 ), and Guangzhou Science and Technology Project (No.: 202102020932 ). Publisher Copyright: © 2022 Phytochemical Society of Europe

PY - 2022/10

Y1 - 2022/10

N2 - A promising strategy for treating Alzheimer's disease (AD) is hippocampal neurogenesis enhancement. Tenuigenin (TEN) is a bioactive compound extracted from Polygala tenuifolia that is widely used for treating amnesia in Chinese medicine. However, whether TEN is effective in treating AD through hippocampal neurogenesis is not fully clear. This study aimed to explore the pharmacologic effect and underlying mechanism of TEN on hippocampal neurogenesis and cognitive deficit amelioration in AD. In an in vivo study, TEN administration significantly ameliorated the cognitive decline in APP/PS1 transgenic AD mice via enhancement of hippocampal neurogenesis, which might be attributed to activation of the GSK-3β/β-catenin pathway. Furthermore, an in silico study suggested that TEN might be directly targeted to GSK-3β. Overall, TEN enhanced hippocampal neurogenesis and consequently ameliorated cognitive deficits via GSK-3β/β-catenin pathway activation, indicating that TEN might be a promising novel agent for AD treatment.

AB - A promising strategy for treating Alzheimer's disease (AD) is hippocampal neurogenesis enhancement. Tenuigenin (TEN) is a bioactive compound extracted from Polygala tenuifolia that is widely used for treating amnesia in Chinese medicine. However, whether TEN is effective in treating AD through hippocampal neurogenesis is not fully clear. This study aimed to explore the pharmacologic effect and underlying mechanism of TEN on hippocampal neurogenesis and cognitive deficit amelioration in AD. In an in vivo study, TEN administration significantly ameliorated the cognitive decline in APP/PS1 transgenic AD mice via enhancement of hippocampal neurogenesis, which might be attributed to activation of the GSK-3β/β-catenin pathway. Furthermore, an in silico study suggested that TEN might be directly targeted to GSK-3β. Overall, TEN enhanced hippocampal neurogenesis and consequently ameliorated cognitive deficits via GSK-3β/β-catenin pathway activation, indicating that TEN might be a promising novel agent for AD treatment.

KW - Alzheimer's disease

KW - Cognitive deficit

KW - GSK-3β

KW - Hippocampal neurogenesis

KW - Tenuigenin

UR - http://www.scopus.com/inward/record.url?scp=85136160944&partnerID=8YFLogxK

U2 - 10.1016/j.phytol.2022.08.005

DO - 10.1016/j.phytol.2022.08.005

M3 - Journal article

AN - SCOPUS:85136160944

SN - 1874-3900

VL - 51

SP - 109

EP - 113

JO - Phytochemistry Letters

JF - Phytochemistry Letters

ER -

Tenuigenin ameliorates cognitive dysfunction in Alzheimer's disease via hippocampal neurogenesis enhancement

Abstract

Scopus Subject Areas

User-Defined Keywords

Access to Document

Other files and links

Fingerprint

Cite this